Governance Harmony Biosciences Holdings, Inc.

HRMY

US4131971040

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
28.33 ^USD	-0.63%		-0.74%	-24.29%

Feb. 25	Deutsche Bank Adjusts Harmony Biosciences PT to $30 From $31, Maintains Hold Rating	MT
Feb. 24	Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for 2026	CI

Executive Committee: Harmony Biosciences Holdings, Inc.

Manager

Positions heldSince

Jeffrey Dayno

68 year

Chief Executive Officer	2023-01-05
President	2023-01-05

Brennan Doyle

Investor Relations Contact

2024-05-31

Audrey Murphy

Human Resources Officer

Ulrich Christian

General Counsel	2020-12-31
Corporate Secretary	-

Sandipkumar S. Kapadia

56 year

Chief Administrative Officer	2023-09-29
Director of Finance/CFO	2021-03-28

David Bradshaw

64 year

Chief Tech/Sci/R&D Officer

Tricia Glover

Compliance Officer

Kumar Budur

55 year

Chief Tech/Sci/R&D Officer

2024-04-30

Composition of the Board of Directors: Harmony Biosciences Holdings, Inc.

Director

CommitteesSince

Jeffrey Aronin

58 year

Chairman

2017-07-24

Gary Sender

64 year

Audit Committee Chair	2021-09-07
Compensation Committee Chair	2021-09-07
Compensation Committee	2020-07-31

R. Graf

61 year

Audit Committee	2020-11-10
Finance Committee Chair
Audit Committee Chair	2024-07-18

Ron Philip

Audit Committee	2025-04-06
Governance Committee	2025-04-06
Nominating Committee	2025-04-06

Andreas Wicki

66 year

Audit Committee
Compensation Committee

Juan Sabater

61 year

Governance Committee Chair
Nominating Committee Chair

Linda Szyper

60 year

Governance Committee	2021-11-17
Nominating Committee	2021-11-17

Antonio Gracias

55 year

Compensation Committee Chair

Peter Anastasiou

55 year

Compensation Committee

2023-11-04

Jeffrey Dayno

68 year

Director/Board Member

2023-04-23

Latest Appointments: Harmony Biosciences Holdings, Inc.

25-04-04	Harmony Biosciences Holdings, Inc. Appoints Ron Philip to its Board of Directors, Audit Committee and Nominating and Corporate Governance Committee	CI
25-04-03	Harmony Biosciences Appoints Biotech Leader Ron Philip To Its Board Of Directors	RE
25-03-24	Harmony Biosciences Holdings, Inc. Announces Executive Changes	CI
24-07-01	Harmony Biosciences Holdings, Inc. Announces Resignation of Jack Bech Nielsen from Board	CI
24-05-03	Harmony Biosciences Holdings, Inc. Appoints Kumar Budur as Executive Vice President and Chief Medical & Scientific Officer	CI
23-11-08	Harmony Biosciences Holdings, Inc. Appoints Peter Anastasiou as Class III Director and Member of the Compensation Committee of the Board	CI
23-10-05	Harmony Biosciences Holdings, Inc. Appoints Sandip Kapadia as Chief Administrative Officer	CI

More news

Former Officers and Directors: Harmony Biosciences Holdings, Inc.

Insider

Positions held

SinceUntil

Jeffrey Dierks

Corporate Officer/Principal	2018-06-30	2025-03-30
Sales & Marketing	2017-09-30	2018-06-30

Luis Sanay

Investor Relations Contact

2022-02-28

2024-08-31

Jack Nielsen

Director/Board Member	2017-08-31	2024-06-26
Independent Dir/Board Member	2017-08-31	2024-06-26

Sharon Goldbach

Corporate Officer/Principal

2023-04-30

John Jacobs

Director/Board Member	2018-05-31	2023-01-05
Chief Executive Officer	2018-05-31	2023-01-05
Corporate Officer/Principal	2017-09-30	2018-05-31
President	2018-05-31	2023-01-05

Eric L. Motley

Director/Board Member	2020-11-10	2021-08-29
Independent Dir/Board Member	2020-11-10	2021-08-29

Susan Drexler

Director of Finance/CFO

2019-09-30

2021-03-28

Lisa M. Caperelli

Investor Relations Contact

2019-12-31

2020-12-31

Brian Yoor

Director/Board Member	2020-05-31	-
Independent Dir/Board Member	2020-05-31	-

Aaron Royston

Director/Board Member

2017-08-31

Martin Edwards

Director/Board Member

2017-07-31

Andrew Schiff

Director/Board Member

Bill Gantz

Director/Board Member

Nancy Leone

Public Communications Contact

Age distribution of managers

Parity Men Women

Male	15
Female	4

Of which Executive Committee

Male	6
Female	2

Of which Directors

Male	9
Female	1

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

Employees

293

Sector

Pharmaceuticals

More about the company